Viatris Inc (VTRS)

$14.36 +0.68 (4.97%)
Market Cap 15.76B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 5.87
Forward PE 5.48
Profit Margin -4.30%
Debt to Equity Ratio 1.07
Volume 14,861,700
Avg Vol 8,487,432
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 91%
Beta 0.79
Analysts Sell
Price Target $13.33

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
ShirleyG
ShirleyG Feb. 5 at 4:07 AM
$VTRS Almost there $15📈🔥 But wait...$18 is even better🤑🤑🤑🤑
0 · Reply
Avocado_smash
Avocado_smash Feb. 5 at 3:56 AM
$VTRS MY PT +/- in the next 2 weeks, imo only: 15.26++
0 · Reply
CoulterB
CoulterB Feb. 4 at 8:06 PM
$VTRS very bullish. I think $18 after earnings report.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 4 at 7:02 PM
$VTRS Share Price: $14.29 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.81 – $1.00 Target Zone: $1.38 – $1.69 Potential Upside: 62% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
T_L808
T_L808 Feb. 4 at 5:10 PM
$VTRS temporary ceiling is about to be gone
0 · Reply
PetrCZE
PetrCZE Feb. 4 at 2:46 PM
$VTRS Nice! As always, patience is the KEY! Owning the shares since 2021, thanks to buying the dips and taking dividends, my avg share price is 10.39, so finally some appreciation, although AI rally would have brought higher profits for sure. But not going to sell none of my 5000 shares anytime soon... I believe this is just a start... could follow TEVA...
1 · Reply
Quantumup
Quantumup Feb. 3 at 1:26 PM
H.C. Wainwright reiterated $AQST Buy/$10 $SPRY $NSRX $TEVA $VTRS Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2018676414778630511?s=20
0 · Reply
CoulterB
CoulterB Feb. 2 at 4:45 PM
$VTRS i think the big players are buying today , beginning of the month.
0 · Reply
ItsCarRamRod
ItsCarRamRod Feb. 2 at 1:43 PM
$VTRS looking like a good place to short VTRS again. Lets make it #6.
2 · Reply
BillionerOfKing
BillionerOfKing Feb. 2 at 12:10 PM
$VTRS Current Stock Price: $13.09 Contracts to trade: $13.0 VTRS Feb 20 2026 Call Entry: $0.35 Exit: $0.53 ROI: 50% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on VTRS
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Feb 3, 2026, 4:34 PM EST - 1 day ago

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Feb 3, 2026, 8:30 AM EST - 1 day ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 6:59 AM EST - 15 days ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

LXRX

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:46 PM EST - 22 days ago

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Jan 8, 2026, 9:05 AM EST - 27 days ago

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan 6, 2026, 9:00 AM EST - 4 weeks ago

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 6 weeks ago

Viatris Provides Pipeline Update on Four Regulatory Milestones

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 6:59 AM EST - 7 weeks ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Dec 6, 2025, 9:00 AM EST - 2 months ago

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 11:13 AM EST - 2 months ago

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 11:03 AM EST - 2 months ago

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 2 months ago

Viatris to Participate in Upcoming Investor Conferences

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 8:38 AM EST - 2 months ago

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Nov 13, 2025, 8:00 AM EST - 2 months ago

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:01 PM EST - 3 months ago

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:46 PM EST - 3 months ago

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Nov 6, 2025, 8:16 AM EST - 3 months ago

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Nov 6, 2025, 6:59 AM EST - 3 months ago

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 3 months ago

Viatris Announces Quarterly Dividend

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Oct 17, 2025, 12:18 PM EDT - 3 months ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

TEVA

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 15, 2025, 4:30 PM EDT - 4 months ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Oct 12, 2025, 10:11 AM EDT - 4 months ago

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

AES AMCR ARE BMY CAG CPB DOC

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 8, 2025, 11:00 AM EDT - 4 months ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 1, 2025, 9:00 AM EDT - 4 months ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 4 months ago

Viatris: Indore Plant Could Boost 2026 Numbers

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 19, 2025, 9:00 AM EDT - 6 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Aug 15, 2025, 1:34 PM EDT - 6 months ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BMY BXP CAG CPB CVX

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 11, 2025, 9:29 AM EDT - 6 months ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 6 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 9:36 AM EDT - 6 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 7, 2025, 6:59 AM EDT - 6 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 6 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 6 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 7 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 7 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 7 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 7 months ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 7 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 7 months ago

Viatris: A Contrarian Bet With Virtually No Downside

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 7 months ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE BMY CAG CPB CVX

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 7 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 8 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 9, 2025, 1:06 PM EDT - 8 months ago

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 11:04 AM EDT - 8 months ago

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Jun 2, 2025, 1:12 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 8 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

ShirleyG
ShirleyG Feb. 5 at 4:07 AM
$VTRS Almost there $15📈🔥 But wait...$18 is even better🤑🤑🤑🤑
0 · Reply
Avocado_smash
Avocado_smash Feb. 5 at 3:56 AM
$VTRS MY PT +/- in the next 2 weeks, imo only: 15.26++
0 · Reply
CoulterB
CoulterB Feb. 4 at 8:06 PM
$VTRS very bullish. I think $18 after earnings report.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 4 at 7:02 PM
$VTRS Share Price: $14.29 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.81 – $1.00 Target Zone: $1.38 – $1.69 Potential Upside: 62% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
T_L808
T_L808 Feb. 4 at 5:10 PM
$VTRS temporary ceiling is about to be gone
0 · Reply
PetrCZE
PetrCZE Feb. 4 at 2:46 PM
$VTRS Nice! As always, patience is the KEY! Owning the shares since 2021, thanks to buying the dips and taking dividends, my avg share price is 10.39, so finally some appreciation, although AI rally would have brought higher profits for sure. But not going to sell none of my 5000 shares anytime soon... I believe this is just a start... could follow TEVA...
1 · Reply
Quantumup
Quantumup Feb. 3 at 1:26 PM
H.C. Wainwright reiterated $AQST Buy/$10 $SPRY $NSRX $TEVA $VTRS Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2018676414778630511?s=20
0 · Reply
CoulterB
CoulterB Feb. 2 at 4:45 PM
$VTRS i think the big players are buying today , beginning of the month.
0 · Reply
ItsCarRamRod
ItsCarRamRod Feb. 2 at 1:43 PM
$VTRS looking like a good place to short VTRS again. Lets make it #6.
2 · Reply
BillionerOfKing
BillionerOfKing Feb. 2 at 12:10 PM
$VTRS Current Stock Price: $13.09 Contracts to trade: $13.0 VTRS Feb 20 2026 Call Entry: $0.35 Exit: $0.53 ROI: 50% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ShirleyG
ShirleyG Feb. 2 at 12:47 AM
$VTRS let's goooooo 🚀🔥⚡️ $13-$15📈
0 · Reply
SniperPro
SniperPro Jan. 29 at 9:10 PM
$LXRX I wish $PFE would take over Pilavapadin—they’re the best candidate to market it globally, and they have the right people ready to sell it once approved. $VTRS would be a second choice, since their salespeople are essentially a division trained by and diversified from $PFE. Also, $BMY has a stake in the development of Pilavapadin, so we might already have a partner deal on the books that just hasn’t been announced yet. Dreams do come true! Let’s hope for the best possible outcome 🚀
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 12:36 AM
$VTRS Share Price: $12.96 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $0.30 – $0.37 Target Zone: $0.54 – $0.66 Potential Upside: 71% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ShirleyG
ShirleyG Jan. 24 at 5:09 AM
$VTRS $15 why not🤑🤑🤑🤑🤑🤑🤑🤑
0 · Reply
SniperPro
SniperPro Jan. 23 at 2:47 PM
$JPM $LXRX $NVO $PFE $VTRS B E L I E V E Every wealthy person I’ve ever met had one thing in common: faith. They believed their actions would eventually be rewarded, regardless of current circumstances. That belief kept them going until success became inevitable. PERSISTENCE. Nothing in this world can take the place of good old persistence. Talent won't. Nothing's more common than unsuccessful men with talent. Genius won't. Unrecognized genius is practically a cliche. Education won't. Why the world is full of educated fools. Persistence and determination alone are all powerful. - Ray Kroc Greetings from WallStreet... LFG Winter Storm - Watch!!! STAY SAFE...
1 · Reply
ShirleyG
ShirleyG Jan. 23 at 7:39 AM
$VTRS wow🔥🔥🔥 let's goooo $15🚀🚀🚀
0 · Reply
SniperPro
SniperPro Jan. 22 at 3:52 PM
$JPM $PFE $NVO $VTRS $LXRX Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill January 22, 2026 $1,000,000,000+ 🤑🤑🤑 Following a successful end-of-Phase II meeting with the FDA, Lexicon Pharmaceuticals can now move forward with the late-stage development of its non-opioid analgesic pilavapadin, taking one step closer to what Jefferies estimates is a market opportunity that exceeds $1 billion. https://www.biospace.com/drug-development/lexicon-opens-path-to-1b-opportunity-as-fda-greenlights-phase-iii-for-non-opioid-pill
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 22 at 1:53 PM
$LXRX + $VTRS 🫰
0 · Reply
FalconTech
FalconTech Jan. 21 at 10:24 PM
$VTRS These guys need to up the dividend. One penny would be all it takes to send the right message. That and FDA approval to reopen Indore would result in a meaningful price bump.
0 · Reply
SniperPro
SniperPro Jan. 21 at 7:28 PM
$LXRX $JPM $NVO $VTRS INPEFA LAUNCH - LX9211 P3 NEXT....... SO MUCH WINNING.... LFG!!! Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure. PITTSBURGH, Jan. 20, 2026 Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. https://newsroom.viatris.com/2026-01-20-Viatris-Expands-Innovative-Portfolio-in-Cardiovascular-Diseases-with-the-Companys-First-Launch-of-Inpefa-R-Sotagliflozin-for-the-Treatment-of-Heart-Failure
0 · Reply
prismmarketview
prismmarketview Jan. 20 at 3:53 PM
Viatris (NASDAQ: $VTRS) has launched Inpefa (sotagliflozin) for heart failure in the UAE—its first market outside the U.S.—marking the company’s entry into innovative cardiovascular therapies and kicking off a global roll‑out under its ex‑U.S./Europe license from Lexicon. https://prismmarketview.com/viatris-expands-cardiovascular-portfolio-with-first-launch-of-inpefa-sotagliflozin-for-heart-failure/
0 · Reply
ShirleyG
ShirleyG Jan. 18 at 1:45 AM
$VTRS ~$13 almost there🔥⚡️🚀💸
0 · Reply